Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Shanghai Minimally Invasive Cardiovascular Medical Technology (Group) Co., Ltd. (hereinafter referred to as "Cardiovascular Medical") is one of the subsidiaries of Minimally Invasive Medical Science Co., Ltd. (HK: 0853), established in 2012 and registered in the Times Medical Innovation Park of Shanghai International Medical Park, China. Xinmai Medical successfully landed on the first batch of Science and Technology Innovation Board in July 2019, with stock code: 688016. SH. In recent years, the company has been awarded the titles of Shanghai High tech Enterprise, Shanghai Science and Technology Little Giant Enterprise, Shanghai Enterprise Technology Center, the first batch of specialized, refined, and new "Little Giant" enterprises in China, and a research and development center for multinational corporations; Won the first prize of Shanghai Science and Technology Progress Award in 2020 and 2016, and the second prize of National Science and Technology Progress Award in 2017; Received the Third Pudong New Area Quality Gold Award in 2019 and the Shanghai Quality Management Award in 2019. Xinmai Medical is an emerging high-tech medical group in the field of aortic and peripheral vascular intervention medical devices that integrates research and development, manufacturing, sales, and services. It has three subsidiaries, namely Lanmai Medical (mainly engaged in peripheral vein business), Hongmai Medical (mainly engaged in peripheral artery business), and Tuomai Medical (mainly engaged in tumor intervention business). The company has 13 listed products, mainly including thoracic and abdominal aortic covered stents, intraoperative stents, drug balloon dilation catheters, peripheral vascular balloon dilation catheters, and other products. Among them, 5 products have obtained CE certification, and 6 products have entered the national innovative medical device registration green channel, leading the industry. The products of Heart Pulse Medical have entered over 1300 hospitals nationwide, and the domestic market share of aortic products has reached 28%, ranking first in domestic brand share for many consecutive years. They have been exported to countries and regions such as Europe, Latin America, and Southeast Asia. Xinmai Medical has always been committed to providing accessible, true, good, and beautiful medical solutions for the treatment of blood circulation diseases, and is committed to building a people-oriented global leading emerging high-tech medical group through technological innovation. |
| Headquarter | Shanghai |
| Establish Date | 8/17/2012 |
| Listed Code | 688016.SH |
| Listed Date | 7/22/2019 |
| Chairman | Bloomberg. |
| CEO | Zhu Qing. |
| Website | www.endovastec.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
